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Abstract: Introduction: The recipients of the hematopoietic stem cell transplantation (HSCT) are at increased risk of a 
variety of infections due to their immunocompromised state. The severity of the immunocompromise differs depending 
upon host, underlying disease, comorbidities, type of transplantation, conditioning regimen, and immunosuppressive 
drugs. Pre-engraftment period is attended by neutropenia, mucosal barrier disruption, broad spectrum antibiotic usage 
and invasive procedures like central lines.  
Aim: We sought to evaluate the type and frequency of the infections in the pre-engraftment period in our transplant 
center. 
Methods and Results: We reviewed 17 HSCT cases done in our center over 24 months from August, 2011 upto August, 
2013 which included 11 autologous and 6 allogeneic HSCT cases. We found a total of 20 febrile neutropenic episodes 
with 12 bacterial and 6 fungal infections. Eighteen of the 73 cultures were positive (24.65%). Nine out of 17 patients 
(52.94%) had at least one culture positive. Eight out of 11 bacteria were ESBL producing (extended spectrum beta 
lactamase) and one organism was only sensitive to colistin. Only 2 of the 12 bacteria were gram positive (16.67%). Only 
one stool test was positive for Clostridium deficile. We had only one culture documented fungal infection (Aspergillus 
sinusitis) and 5 presumed Aspergillus infections. 
Conclusion: The incidence of febrile neutropenia is similar to other centers in India and Western world, though the 
organisms are different. Gram negative bacteria continue to be the major threat to hematopoietic cell transplant 
recipients especially in the early post-transplant period in India. 
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INTRODUCTION 
The recipients of the hematopoietic stem cell 
transplantation (HSCT) are at increased risk of a 
variety of infections due to their immunocompromised 
state. The severity of the immunocompromise differs 
depending upon host, underlying disease, 
comorbidities, type of transplantation, conditioning 
regimen, and immunosuppressive drugs. Allogeneic 
HSCT has manifold increased risk than autologous 
HSCT. The post transplantation infections are roughly 
divided into pre-engraftment, immediate post 
engraftment (upto 3 months) and late post engraftment 
(more than 3 months). The mechanism of 
immunosuppression is different in different periods post 
transplantation. Pre-engraftment period is attended by 
neutropenia, mucosal barrier disruption, broad 
spectrum antibiotic usage and invasive procedures like 
central lines [1]. The common organisms expected 
during this period are gram positive and gram negative 
bacteria, gut organisms, viruses like Herpes simplex 
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virus, respiratory and enteric viruses and fungi like 
Candida and Aspergillus species. 
Aim 
To evaluate the types and frequency of the 
infections in the pre-engraftment period in our 
transplant center. 
METHODS 
The patient record files and the final microbiology 
reports were reviewed. All the transplantations were 
done in HEPA filtered, positive pressure rooms, with all 
standard recommended precautions, 1:1 nursing and 
proper central line care (double/triple lumen tunneled). 
All patients underwent baseline blood and nasal swab 
cultures and received treatment if indicated prior to 
entry into the transplantation unit. 
Antimicrobial Prophylaxis  
Acyclovir was started at day +1 and continued until 
engraftment in case of allogeneic transplant recipients. 
Fluconazole prophylaxis was used in all patients 
(allogeneic as well as autologous) till engraftment. 
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Trimethoprim + sulfamethoxazole was started after 
stable engraftment in allogeneic transplant recipients. 
All patients used medicated mouth washes, betadine 
water perianal care, soap water and alcohol hand rub. 
Definitions of Infections 
On documentation of an oral temperature of 100.4 F 
or 100 F for 1 hour, blood cultures and if indicated 
other targeted cultures were taken and empirical 
antibiotics started. First antibiotic used was 
cefoperazone + sulbactum. If the fever did not resolve 
in 2-3 days antibiotics were escalated to carbapenums 
or as per bacterial sensitivities and serum 
galactomannan checked on clinical or chest X-ray 
suspicion. Antifungal used for treatment if indicated 
was amphotericin-B. We reviewed the microbiology 
results including bacterial, fungal, viral and other 
organisms from wide range of the clinical specimens 
including blood, urine, stool, throat swabs, 
endotracheal tube secretions, and other specimens. 
RESULTS 
We reviewed 17 HSCT cases done in our center 
over 24 months from Aug 2011 upto August 2013 
which included 11 autologous and 6 HSCT cases. The 
indications for the transplantation were multiple 
myeloma for eight, non-Hodgkin lymphoma for two, 
Hodgkin lymphoma for one, chronic myeloid leukemia 
(CML) for one, Sickle cell disease for one, aplastic 
anemia for two (one with paroxysmal nocturnal 
hemoglobinuria- PNH), hemophagocytic histiocytosis 
(HLH) for one and acute myeloid leukemia for one. 
There were 10 males and 7 females. The median age 
was 41 years (range from 7 years to 71 years). 
The conditioning regimen used were high dose 
melphalan for multiple myeloma, BEAM (carmustine, 
etoposide, cytarabine, melphalan) for lymphoma, and 
busulfan/cyclophosphamide with or without antithymo- 
cyte globulin for allogeneic transplantation. 
Mean engraftment was on day 12 of the 
transplantation in autologous and day 16 in the alloge- 
neic transplantation. Engraftment was not reached in 
the three patients who died. 
Bacterial Infections 
 We found a total of 11 bacterial infections (Table 1) 
out of the 20 febrile episodes (55%). A total of 73 
blood/urine/endotracheal secretions/swabs cultures 
were sent for the evaluation of the post transplantation/ 
pre-engraftment febrile neutropenia in addition to the 
number of follow up cultures to document resolution of 
the previous infection. Eighteen of the 73 cultures were 
positive (24.65%). Nine out of 17 patients (52.94%) had 
at least one culture positive. Eight out of 12 bacteria 
were ESBL producing (extended spectrum beta 
lactamase) and one organism was only sensitive to 
Colistin. The source of the positive cultures were blood 
(11/18, 61.1%), urine (2/18, 11.1%), throat swab (1/18, 
5.5%) and endotracheal secretions (4/18, 22.2%). Only 
2 of the 12 bacteria were gram positive (16.67%). The 
patients who died had multidrug resistant gram 
negative bacterial infections (E. coli, Acinetobacter and 
Klebsiella species). All the transplantation subjects had 
diarrhea at least once during the hospitalization. Ova 
and cysts, culture, Clostridium deficile toxin were 
checked in all the cases. All of these were negative 
except one case of Clostridium deficile diarrhea which 
resolved after oral vancomycin. 
Fungal Infections 
Serum Galactomannan was checked in each 
episode of febrile neutropenia and also routinely 
weekly in case of allogeneic transplantations. Six of the 
20 febrile neutropenic episodes were positive for serum 
galactomannan with one of the patients having fungal 
sinusitis documented with culture (Aspergillus species) 
and treated with liposomal amphotericin-B.  
Routine viral screening for HSV, CMV, HIV, HBsAg 
and Anti-HCV was done prior to the transplantation. 
We did not see any reactivation of CMV or HSV. We 
had one death amongst autologous transplant patients 
and two deaths amongst allogeneic transplantation 
patients, all of which were due to multi drug resistant 
bacterial infections. 
DISCUSSION 
The major cause of the mortality following 
hematopoietic stem cell transplantation is infection. In 
the pre-engraftment period, mucositis, low neutrophils 
due to the conditioning regimen, immunosuppressive 
drugs and central venous lines increase the chances of 
the serious infections.  
Bacterial Infections 
Due to the defective phagocytosis, bacterial 
infections are very common. Common gram positive 
bacteria [2] include Coagulase Negative 
Staphylococcus, Staphylococcus Aureus, Streptococci, 
and Enterococci. Common gram negative bacteria
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Table 1: Bacterial Culture Positive Febrile Neutropenias 
S. No. Organism 
Isolated 
Post 
Transplant 
day 
Clearance/ 
Outcome 
Source Sensitivity Pattern Resistance Pattern Duration of 
Antibiotics, Dose 
and Name 
1 Coagulase 
negative 
staphylococcus 
7 Resolved Blood Amoxicillin/clavulinate, 
Cefazolin, Vancomycin, 
Teicoplanin, 
Clindamycin, Linezolid, 
Cefipime, Ciprofloxacin 
Erythromycin 
Co-trimoxazole 
Cefipime 2 grams 
IV Q12H x7d 
2 Klebsiella 
pneumonia 
(ESBL) 
2 Resolved Blood Amikacin, Meropenum, 
Imepenum, 
Piperacillin/tazobactum 
(Int), Cefoperazone/ 
sulbactum(Int) 
Ceftazidime, Ceftriaxone, 
Ciprofloxacin, Offloxacin, 
Tobramycin, Netilimycin, 
Cefotaxime, Aztreonam, 
Cefoperazone 
Cefoperazone/ 
sulbactum(Int) 
2gms IV Q12H x 14 
days 
Plus Amikacin IV 750 
mg IV Q24H x 14 
days 
3 Coagulase 
negative 
staphylococcus 
4 Resolved Blood Amoxicillin/clavulinate, 
Erythromycin, 
Cefazolin, Clindamycin, 
Cefuroxime, Cefipime, 
Ciprofloxacin, Co-
trimoxazole 
None Cefoperazone/ 
sulbactum(Int) 
2gms IV Q12H x 11 
days 
4 Pseudomonas 
aueruginosa 
28 Resolved Sinus 
aspiration 
Gentamycin, Amikacin, 
Ceftazidime, 
Ciprofloxacin, 
Tobramycin, Imepenum, 
Piperacillin/tazobactum, 
Cefoperazone/ 
sulbactum, Cefipime 
None Imepenum IV 500 
mg Q8H x 12 dyas 
5 E. Coli 
(ESBL) 
31 Resolved Urine 
 
Amikacin, Imepenum, 
Piperacillin/tazobactum, 
Cefoperazone/ 
sulbactum, 
Gentamycin, Ceftazidime, 
Ceftriaxone, Ciprofloxacin, 
Co-trimoxazole, Cefotaxime, 
Tobramycin, Cefipime, 
Ceftizoxime, Aztreonam, 
Cefoperazone 
Imepenum IV 500 
mg Q8H x 12 days 
6 E. Coli 
(MDR) 
3 Death Blood Colistin Gentamycin, Amikacin, 
Ceftazidime, Ceftriaxone, 
Ciprofloxacin, Cefotaxime, 
Tobramycin, Cefipime, 
Ceftizoxime, 
Piperacillin/tazobactum, 
Aztreonam, 
Cefoperazone/sulbactum, 
Meropenum, Imipenum 
Colistin 6 M IU iv 
Q12H x 7d 
7 Klebsiella 
pneumonia 
3 Resolved Throat 
swab 
Gentamycin, Amikacin, 
Meropenum, Imipenum, 
Ertapenum 
Ceftazidime, Ceftriaxone, 
Ciprofloxacin, Co-
trimoxazole, Cefotaxime, 
Tobramycin, Cefipime, 
Cetizoxime, Aztreonam, 
Cefoperazone 
Meropenum 2 grams 
IV Q8H x 16 days 
8 E. Coli 6 Resolved Urine Gentamycin, Amikacin, 
cefoperazone / 
sulbactum, Piperacillin / 
Tazobactum, Imipenum, 
Meropenum, Ertapenum 
Ceftazidime, Ceftriaxone, 
Cefotaxime, Cefipime, 
Ceftizoxime, Cefoperazone 
 
Meropenum 2 grams 
IV Q8H x 13 days 
9 Acinetobacter 
baumanni (MDR) 
17 Death Endotrache
al tube 
secretion 
Colistin 
Tigecycline 
Ceftazidime, Ceftriaxone, 
Cefotaxime, Cefipime, 
Cefoperazone/sulbactum, 
Gentamycin, Amikacin, 
Offloxacin, Co-trimoxazole, 
Tobramycin, Netilimycin, 
Meropenum 2 grams 
IV Q8H x 6 d 
Plus 
Colistin 6 M IU IV 
Q12H x 3 days 
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(Table 1). Continued..  
S. No. Organism 
Isolated 
Post 
Transplant 
day 
Clearance/ 
Outcome 
Source Sensitivity Pattern Resistance Pattern Duration of 
Antibiotics, Dose 
and Name 
10 Klebsiella 
pneumonae 
(MDR) 
14 Death Throat 
swab 
Colistin 
Tigecycline 
Ceftazidime, Ceftriaxone, 
Cefotaxime, Cefipime, 
Cefoperazone/sulbactum, 
Gentamycin, Amikacin, 
Offloxacin, Co-trimoxazole, 
Tobramycin, Netilimycin, 
Meropenum 
Meropenum 2 grams 
IV Q8H x 6 d 
Plus 
Colistin 6 M IU IV 
Q12H x 3 days 
11 Klebsiella 
pneumonae 
(MDR) 
4 Death Endotrach
eal tube 
suction 
Colistin 
Tigecycline 
Ceftazidime, Ceftriaxone, 
Cefotaxime, Cefipime, 
Cefoperazone/sulbactum, 
Gentamycin, Amikacin, 
Offloxacin 
Co-trimoxazole 
Tobramycin 
Netilimycin 
Meropenum 
Meropenum 2 grams 
IV Q8H x 4 days 
Plus colistin 6 M IU 
IV Q12H 
 
Table 2: All the Observed Infections 
Coagulase negative 
staphylococcus 
2 
Gram positive 3 
Clostridium deficile 2 
Klebsiella P. 4 
E. coli 3 
Pseudomonas A. 1 
Bacterial 
Gram negative 9 
Acinetobacter 1 
Viral None 
Candida None   
Presumed  5 Fungal 
Aspergillus 6 
Culture positive 1 
Parasite None 
 
 [1] include Enterobacteracae like E. coli, 
Enterobacter, Klebsiella species; others include 
Pseudomonas species. Anaerobes are not very 
uncommon and include Clostridium species. Woo PC, 
et al. from Hong Kong suggested in their study [3] that 
bacillus may be responsible for the culture negative 
febrile neutropenias. 
Viral Infections 
Reactivation of Herpes simplex (HSV) is common 
and is comparable between allogeneic and autologous 
transplantation [4]. The median time of reactivation is 
about 3 weeks [5] and HSV-1 is more common than 
HSV-2. Other viruses include respiratory viruses like 
Respiratory syncytial virus, Influenza and Parainfluenza 
viruses. 
Fungal Infections 
Fungal infections are significantly more common in 
allogeneic as compared to the autologous 
transplantation. Candida and Aspergillus species are 
the commonest killers. Candida used to be the 
commonest before the advent of routine triazole 
prophylaxis [6, 7] post transplantation though part of 
this achievement has been blunted by appearance of 
the resistant Candida strains like C. krusei and C. 
glabrata [8-10]. Aspergillus and Fusarium are the 
common mold infections, though more common in 
allogeneic than autologous transplantation[11, 12]. 
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B. George et al. [13] presented a large retrospective 
series from India in 2004 of 297 allogeneic 
transplantation patients. This study included even the 
post engraftment period and reported 415 documented 
infections among 304 transplants. All patients 
developed febrile neutropenia which is fairly constant in 
over the board studies. We had 66.67% bacterial 
infections, which is almost double as compared to their 
series though gram negative bacteria topped our list 
too at 75% as compared to their 80%). The pattern of 
gram negative organisms is significantly different as 
Klebsiella and E. coli together constituted 58.33% 
amongst the gram negative group. The major bacterial 
group in their series was non-fermenting gram negative 
bacteria at 24.9%. These differences could be 
attributed to the different hospital flora in these studies. 
We did not see any viral infections as compared to their 
study, because their study included the post-
engraftment follow up period too. The Aspergillus was 
the most common fungal infection in their study too but 
Candida and Zygomycetes were also seen and our 
study had only Aspergillus fungal infections. This may 
be because of the less number of the patients in our 
study. 
Gudiol C, et al. [14] has presented an interesting 
study of pre-engraftment versus post engraftment 
blood stream infections in hematopoietic stem cell 
transplant recipients. They concur with the different 
etiological factors in the two settings and have 
indicated worse outcome in the late infections as per 
their high case fatality ratios. Another fact in 
concordance with earlier studies remains that Gram 
positive infections are more prevalent than Gram 
negative bacterial infections which has been 
consistently shown to be different in Indian 
subcontinent as evidenced by the above study by B 
George, et al. [13]. 
Kinnebrew, et al. [15] reviewed a 13 year 
observational data from Memorial Sloan Kettering 
Cancer Center of hematopoietic stem cell transplant 
recipients. Fecal specimens from 37patients (39%) 
were found to harbor C. difficile. Early-transplant 
Clostridium deficile infection (CDI) was diagnosed in 16 
of 94 (17%) patients undergoing allogeneic-HSCT. This 
is a significant percentage of patients in this critical 
period. Though we did Clostridium deficile testing in all 
patients with diarrhea, we found only one positive case 
in our study. 
The mortality in our study was related to the multi 
drug resistant (MDR) bacteria and thus raises concerns 
regarding the prevalence of the MDR bacteria. We 
understand from our study that the spectrum of 
infections may be different in different setting with 
regard to the local flora. 
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